REDMILE β Full Portfolio
39 tracked investments Β· listed companies and verified rows first
Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch.
AI & Machine LearningBiotechDeep TechPortland, US
Sean McClain(Executive Officer)inPhil Barish(Executive Officer)inZachariah Jonasson(Chief Financial Officer and Chief Business Officer)Shelby Walker(Chief Legal Officer)inRansi Somaratne(Chief Medical Officer)Andreas Busch(Chief Innovation Officer)in
Co-investorsDas & Co.Oregon Venture FundPhoenix Venture PartnersTachyon VenturesTau VenturesBiotechnology Value Fund+2 more
Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.
BiotechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)
Co-investorsFidelity InvestmentsForesite CapitalGV (Google Ventures)MITHRILMithril Capital ManagementOrbiMed+3 more
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)inBruce Booth(Chair)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures Fund+5 more
Neurogene develops gene therapy treatments for rare neurological diseases.
BiotechDeep TechDigital HealthLongevityMedical Devices
Rachel McMinn(Founder and Chief Executive Officer)inRachel McMinn, Ph.D.(Founder and Chief Executive Officer)
Co-investorsEcoR1 CapitalCasdin CapitalRTW Investments L.P.
Replimune is a biotech company developing oncolytic immunotherapies designed to activate immune responses against difficult-to-treat cancers.
BiotechHealthtechMedical Devices
Robert Coffin(Founder and Chief Scientist)Sushil Patel(Chief Executive Officer)Emily Hill(Chief Financial Officer)Konstantinos Xynos(Chief Medical Officer)
Co-investorsAtlas VentureBain Capital Life SciencesForesite Capital
Shattuck Labs is a biotechnology company developing biologic medicines targeting TNF receptors, including the TL1A/DR3 axis, for patients with cancer and inflammatory or life-altering diseases.
BiotechHealthtechAustin, US
Josiah Hornblower(President/CEO)inTaylor(Co-founder & Chief Executive Officer, Board Member)
BoardWalter Loewenbaum(Director)
Co-investorsEcoR1 CapitalHatteras Venture PartnersOrbiMedT. Rowe Price
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+8 more
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.
BiotechHealthtechMedical DevicesAustin, US
Shanshan Xu(Founder & Chief Executive Officer)inHelmut Jeggle(Co-Founder)inThang Ho(Chief Development Officer)inCrystal MacKay(Chief Operating Officer)in
Co-investorsINCE CapitalRA CapitalBiotechnology Value FundJanus Henderson InvestorsSalvia
GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function.
BiotechDeep TechHealthtechCambridge, US
Daniel J Mandell(Chief Executive Officer)Tracey Lodie(Executive Officer)inChristopher Gregg(Director)
BoardMing Fang(Director)Bruce Beutel(Director)Dan Becker(Director)
Co-investorsLeaps by BayerDigitalis VenturesDreamers VCRising TideAtlas VentureInnovation Endeavors+1 more
Home Biosciences was a venture builder in Continental Europe dedicated to creating and scaling biotech companies through an asset-centric, hub-and-spoke model, working with academics and scientists on drug discovery and molecular profiling projects.
AI & Machine LearningBiotechHealthtech
David Schilansky(Co-founder & Non-executive Chairman)inMagali Richard(Co-founder)in
Co-investorsSofinnova Partners
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)inKaren Flick(General Counsel)in
Co-investorsVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsInvusJanus Henderson Investors+4 more
Redx is a clinical-stage biotechnology company developing small molecule targeted medicines focused on fibrotic diseases, leveraging ROCK pathway inhibitors and novel targets.
BiotechHealthtechMedical Devices
Lisa Anson(Chief Executive Officer)
BoardBernard Coulie(Independent Director)
Co-investorsAbingworthPerscitus LLP
Ambrosia Bio produces rare sugars such as Allulose as low- to no-calorie replacements for sugar, offering a similar taste, sweetness, and textural profile without artificial aftertaste.
BiotechFoodTechJerusalem, IL
Co-investorsAnimoca BrandsBrinc
Attralus develops pan-amyloid removal (PAR) therapeutics β biologics and imaging agents designed to bind and remove toxic amyloid β to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)inGreg Bell(Executive Officer)
Co-investorsAlpha Wave GlobalBioBritvenBio PartnersJanus Henderson InvestorsSamsara BioCapitalvenBio Global Strategic+1 more
Clear Labs develops fully automated next-generation sequencing (NGS) platforms that process genomic data into insights for research and surveillance applications across infectious disease, food safety, and oncology.
BiotechData & InfrastructureDeep TechHealthtechMedical DevicesSan Carlos, US
Sasan Amini(Co-founder & CEO)inRamin Khaksar(Executive Officer)inEdward Fan(Executive Officer)inBrodie Flanders(Executive Officer, Director)Kazutaka Ohno(Executive Officer)Farzad Naimi(Executive Officer, Director)
Co-investorsMenlo VenturesKhosla VenturesNimble VenturesDentsu VenturesFelicis VenturesNimble Partners+5 more
Climb is a French wealth management service that combines advisors with technology to grow clients' assets through an open-architecture selection of investment products (life insurance, retirement PER, real estate, private equity, tax-reduction schemes, crypto).
FintechSaaS
Aldric EmiΓ©(CEO)in
Co-investorsKima VenturesAlly Bridge GroupRA Capital
DealForma provides a data platform and analyst support for biopharma business development teams to research partnerships, deals, funding trends, and therapeutic areas.
BiotechData & InfrastructureHealthtechSaaS
Chris
Co-investorsTinySeedAlgerRA CapitalRTW Investments L.P.Sofinnova Ventures
Deciphera is a pharmaceutical company focused on developing treatments for people living with cancer.
Biotech
Daniel Flynn(Founder)in
Co-investorsFrazier Life SciencesNew Leaf Venture PartnersViking Global Investors
BiotechWaltham, US
Daniel F. Flynn, Ph.D.(Executive Officer)Oliver Rosen, M.D.(Executive Officer)inThomas Kelly(Executive Officer)Michael Taylor(Executive Officer, Director)in
BoardMichael Ross(Director)Liam Ratcliffe, M.D., Ph.D.(Director)
Co-investorsFrazier Life SciencesViking Global Investors
Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases.
BiotechDeep Tech
Co-investorsOrbiMedOxford Science EnterprisesPanacea VentureCowen Healthcare InvestmentsGV (Google Ventures)
Genalyte develops Merlin, a real-time diagnostic system that performs laboratory testing directly in clinical settings and integrates results with electronic health records.
Digital HealthHardwareHealthtechMedical DevicesSan Diego, US
Cary Gunn(Co-founder and Chief Technical Officer)in
Co-investorsBioBritBoutique Venture PartnersClaremont Creek VenturesFusionX VenturesIPD CapitalSamsara BioCapital+3 more
Impulse Dynamics develops implantable medical device technology for cardiac care, with a background in biomedical research and implantable cardiac electronics.
BiotechHardwareHealthtechMedical DevicesDublin 2, US
Shlomo Ben-Haim(Director)Jason Spees(Chief Executive Officer)inPaul Bae(Chief Administrative Officer and General Counsel)inDavid Prutchi(Executive Vice President, Chief Technology Officer)inRichard J. Buchholz(Chief Financial Officer)Anthony Hong(Chief Science and Strategy Officer)in
Co-investorsAmzak HealthAlgerBraidwellEssex Woodlands Healthcare PartnersSands Capital VenturesSignet Healthcare Partners
LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.
AI & Machine LearningBiotechHealthtechMedical Devices
Ton AdanginHans van der Vliet(Head of Innovation)inSteve Hurly(Chief Executive Officer)Oxana Polyakova(Chief Scientific Officer)in
Co-investorsMRL Ventures FundSanofi VenturesYsios CapitalGilde Healthcare
Mnemo Therapeutics is a Paris-based clinical-stage biotech developing cell therapies using its EnfiniT epigenetic antigen discovery platform to target tumor-specific antigens for CAR-T therapies.
Co-investorsSofinnova PartnersAlexandriaCasdin Capital
HealthtechWest Lafayette, US
Philip Low, Ph.D.(Director)Sunil Singhal, M.D.(Director)Isaac Barchas(Director)Clay B. Siegall, Ph.D.(Executive Officer, Director)Ronald Martell(Director)inFranklyn Prendergast, M.D., Ph.D.(Director)
Co-investorsEcoR1 CapitalArsenal Bridge VentureJanus Henderson Investors
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.
AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US
Nancy Stagliano(CEO)in
Co-investorsKleiner PerkinsSoftBank GroupSoftBank Vision FundWestlake Village BioPartnersACORN BIOVENTURESCowen Healthcare Investments+1 more
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Co-investorsAndreessen HorowitzARCH Venture PartnersiGlobe PartnersAgent CapitalNewpath Partners
Saluda Medical develops the Evoke spinal cord stimulation (SCS) system, which records the spinal cord's physiologic response to stimulation using Evoked Compound Action Potentials (ECAPs).
Deep TechHealthtechMedical DevicesBloomington, US
Greg Plamondon(Executive Officer)inKristin Caplice(Executive Officer)inBarry Regan(Executive Officer, Director)inJames Schuermann(Director, Executive Officer)Geoffrey Kinghorn(Director)
BoardJuan-Pablo Mas(Director)in
Co-investorsAction Potential Venture Capital Ltd.Fidelity InvestmentsT. Rowe PriceWellington Management
Scanadu is a medical content and research provider offering health education, product reviews, and guides focused on fitness, wellness, CBD therapies, and medical innovations.
Digital HealthHealthtechWellness & FitnessMoffett Field, US
Bob Gardner(Executive Officer)Jamie Tenedorio(Executive Officer)Daya Ranamukhaarachchi(Executive Officer)Jackie Schneider(Executive Officer)
BoardWalter De Brouwer(Executive Officer, Director)Sam De Brouwer(Executive Officer)in
Co-investorsVTF CapitalAME Cloud VenturesClaritas CapitalFosun InternationaliGlobe PartnersRelay Ventures+1 more
Sensorion is a French clinical-stage biopharmaceutical company founded in 2009 in Montpellier that develops gene-therapy and small-molecule treatments for inner-ear disorders like genetic deafness and tinnitus.
Co-investorsSofinnova PartnersInvus
Provides pharmaceutical R&D services via the Cyto-Mine machine for single-cell analysis and characterisation.
Co-investors24 HaymarketQVenturesProvidence Investment Company LimitedSofinnova Partners
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent Capital+9 more
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalFlagship Ventures
Thriveworks provides therapy and psychiatric medication management services, helping clients find providers and book sessions, with insurance accepted.
Digital HealthHealthtechMedia & EntertainmentMental HealthWellness & Fitness
Anthony Centore(Executive Officer, Director)Jon Santemma(Executive Officer, Director)Terry Wang(Director)David Kim(Director)
Co-investorsRogue Insight CapitalFidelity InvestmentsRA CapitalWellington Management
Virta provides roaming management software that enables charging station operators to connect their infrastructure to a network of hundreds of thousands of charge points across 35+ countries.
CleantechEnergyEnterprise SoftwareFintechMobility & TransportationSaaSHelsinki, FI
Juhani Hintikka(CEO)in
Co-investorsFuture Energy VenturesHelen VenturesJolt CapitalObvious VenturesSciFi VCTiger Global Management+2 more
Other
Tracked investments with no reachable website or further public details β typically companies that wound down, renamed, or were absorbed.
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.